3.27
-0.06(-1.80%)
Currency In USD
Address
21 Erie Street
Cambridge, MA 02139
United States of America
Phone
617-564-0013
Sector
Healthcare
Industry
Biotechnology
Employees
214
First IPO Date
October 20, 2022
| Name | Title | Pay | Year Born |
| Allan Reine | Chief Executive Officer & Director | 924,027 | 1975 |
| Jeffrey D. Marrazzo | Executive Chair | 85,792 | 1979 |
| Matthew J. Hawryluk | Chief Business Officer | 680,800 | 1978 |
| Ann L. Lee | Chief Technical Officer | 684,782 | 1962 |
| Keith Michael Gottesdiener | Consultant | 1.08M | 1954 |
| Andrew Anzalone | Co-Founder | 0 | 1987 |
| David R. Liu | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Mohammed Asmal | Senior VP & Head of Clinical | 0 | N/A |
| Ryan E. Brown | Chief Legal Officer | 0 | 1978 |
| Niamh Alix | Chief Human Resources Officer | 0 | N/A |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.